Isotonic designs for phase I trials

The purpose of a phase I trial in cancer is to determine the level (dose) of the treatment under study that has an acceptable level of adverse effects. Although substantial progress has recently been made in this area using parametric approaches, the method that is widely used is based on treating s...

Full description

Saved in:
Bibliographic Details
Main Authors: LEUNG, Denis H. Y., WANG, You-Gan
Format: text
Language:English
Published: Institutional Knowledge at Singapore Management University 2002
Subjects:
Online Access:https://ink.library.smu.edu.sg/soe_research/2155
https://ink.library.smu.edu.sg/context/soe_research/article/3155/viewcontent/IsotonicDesignsPhaseITrials_2001.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Singapore Management University
Language: English
id sg-smu-ink.soe_research-3155
record_format dspace
spelling sg-smu-ink.soe_research-31552018-02-15T03:24:42Z Isotonic designs for phase I trials LEUNG, Denis H. Y. WANG, You-Gan The purpose of a phase I trial in cancer is to determine the level (dose) of the treatment under study that has an acceptable level of adverse effects. Although substantial progress has recently been made in this area using parametric approaches, the method that is widely used is based on treating small cohorts of patients at escalating doses until the frequency of toxicities seen at a dose exceeds a predefined tolerable toxicity rate. This method is popular because of its simplicity and freedom from parametric assumptions. In this paper, we consider cases in which it is undesirable to assume a parametric dose-toxicity relationship. We propose a simple model-free approach by modifying the method that is in common use. The approach assumes toxicity is nondecreasing with dose and fits an isotonic regression to accumulated data. At any point in a trial, the dose given is that with estimated toxicity deemed closest to the maximum tolerable toxicity. Simulations indicate that this approach performs substantially better than the commonly used method and it compares favorably with other phase I designs. 2002-02-01T08:00:00Z text application/pdf https://ink.library.smu.edu.sg/soe_research/2155 info:doi/10.1016/S0197-2456(00)00132-X https://ink.library.smu.edu.sg/context/soe_research/article/3155/viewcontent/IsotonicDesignsPhaseITrials_2001.pdf http://creativecommons.org/licenses/by-nc-nd/4.0/ Research Collection School Of Economics eng Institutional Knowledge at Singapore Management University Continual reassessment method Dose escalation Isotonic regression Maximum tolerated dose Phase I trials Up-and-down method Econometrics Medicine and Health Sciences
institution Singapore Management University
building SMU Libraries
continent Asia
country Singapore
Singapore
content_provider SMU Libraries
collection InK@SMU
language English
topic Continual reassessment method
Dose escalation
Isotonic regression
Maximum tolerated dose
Phase I trials
Up-and-down method
Econometrics
Medicine and Health Sciences
spellingShingle Continual reassessment method
Dose escalation
Isotonic regression
Maximum tolerated dose
Phase I trials
Up-and-down method
Econometrics
Medicine and Health Sciences
LEUNG, Denis H. Y.
WANG, You-Gan
Isotonic designs for phase I trials
description The purpose of a phase I trial in cancer is to determine the level (dose) of the treatment under study that has an acceptable level of adverse effects. Although substantial progress has recently been made in this area using parametric approaches, the method that is widely used is based on treating small cohorts of patients at escalating doses until the frequency of toxicities seen at a dose exceeds a predefined tolerable toxicity rate. This method is popular because of its simplicity and freedom from parametric assumptions. In this paper, we consider cases in which it is undesirable to assume a parametric dose-toxicity relationship. We propose a simple model-free approach by modifying the method that is in common use. The approach assumes toxicity is nondecreasing with dose and fits an isotonic regression to accumulated data. At any point in a trial, the dose given is that with estimated toxicity deemed closest to the maximum tolerable toxicity. Simulations indicate that this approach performs substantially better than the commonly used method and it compares favorably with other phase I designs.
format text
author LEUNG, Denis H. Y.
WANG, You-Gan
author_facet LEUNG, Denis H. Y.
WANG, You-Gan
author_sort LEUNG, Denis H. Y.
title Isotonic designs for phase I trials
title_short Isotonic designs for phase I trials
title_full Isotonic designs for phase I trials
title_fullStr Isotonic designs for phase I trials
title_full_unstemmed Isotonic designs for phase I trials
title_sort isotonic designs for phase i trials
publisher Institutional Knowledge at Singapore Management University
publishDate 2002
url https://ink.library.smu.edu.sg/soe_research/2155
https://ink.library.smu.edu.sg/context/soe_research/article/3155/viewcontent/IsotonicDesignsPhaseITrials_2001.pdf
_version_ 1770574028471271424